Project description:Diffuse large B cell lymphoma is a heterogenous malignancy that is diagnosed in over 60,000 patients each year. Interleukin-21 has been shown to induce apoptosis in certain B cells originating from mice. Diffuse large B cell lyphomas express the Interleukin-21 Receptor yet the effects of Interleukin-21 on this malignancy are uknown. Identified genes responsive to IL-21 treatment in diffuse large B cell lymphoma.
Project description:This SuperSeries is composed of the following subset Series: GSE30357: Chip-chip from human diffuse large B cell lymphoma cell lines with IRF8 GSE30358: Mouse B cell lymphoma cell lines:IRF8 knockdown cells vs. Control GSE30519: Chip-chip from mouse diffuse large B cell lymphoma cell lines with IRF8 GSE30520: Chip-chip from mouse diffuse large B cell lymphoma cell lines with PU.1 Refer to individual Series
Project description:Plasmablastic lymphoma is an aggressive B-cell lymphoma with an immunoblastic/large cell morphology anda plasmacytic differentiation. The differential diagnosis with Burkitt lymphoma, plasma cell myeloma and some variants of diffuse large B-cell lymphoma may be challenging due to the overlapping morphological, genetic and immunophenotypic features. Furthermore, the profile of chromosomal alterations is not well known.
Project description:microRNAs er are group of short noncoding RNAs that regulate gene expression at the posttranslational level. It has been shown that mirs are independent predictios of outcome in patients with diffuse large b cell lymphoma treated with r-chop. Outcome in patients with dlbcl lymphoma treated with r-chop. Based on the measured GI50 in 60 human cell lines.
Project description:We have included human samples including bladder tissue, Cervical tissue, Colorectal tissue, diffuse large B-cell lymphoma, Gastric tissue, glioblastoma multiforme, K562 cell, thyroid tissue, Plasma, Leukemia, Sarcoma, squamous cell lung carcinoma, hepatocellular K562 cell lines. The details are described in Table 1 and Supplementary Table 1.
Project description:microRNAs er are group of short noncoding RNAs that regulate gene expression at the posttranslational level. It has been shown that mirs are independent predictios of outcome in patients with diffuse large b cell lymphoma treated with r-chop. Outcome in patients with dlbcl lymphoma treated with r-chop. Based on the measured GI50 in 60 human cell lines. 116 DLBCL samples
Project description:The purpose of this phase 2 study is to evaluate the efficacy and safety of NIR178 in combination with PDR001 in multiple solid tumors and diffuse large B-cell lymphoma (DLBCL) and further explore schedule variations of NIR178 to optimize immune activation through inhibition of A2aR.
